Drug repurposing for Alzheimer's disease and other neurodegenerative disorders

被引：0
|
作者：
Cummings, Jeffrey L. [1 ]
Zhou, Yadi [2 ]
Van Stone, Alexandra [3 ]
Cammann, Davis [4 ]
Tonegawa-Kuji, Reina [2 ]
Fonseca, Jorge [5 ]
Cheng, Feixiong [2 ,6 ,7 ,8 ]
机构：
[1] Univ Nevada Las Vegas UNLV, Chambers Grundy Ctr Transformat Neurosci, Kirk Kerkorian Sch Med, Dept Brain Hlth, Las Vegas, NV 89106 USA
[2] Cleveland Clin, Genom Med Inst, Lerner Res Inst, Cleveland, OH 44195 USA
[3] Roseman Univ Hlth Sci, Las Vegas, NV 89135 USA
[4] Univ Nevada Las Vegas UNLV, Nevada Inst Personalized Med, Las Vegas, NV USA
[5] Univ Nevada Vegas UNLV, Howard R Hughes Coll Engn, Dept Comp Sci, Las Vegas, NV 89154 USA
[6] Case Western Reserve Univ, Lerner Coll Med, Dept Mol Med, Cleveland Clin, Cleveland, OH 44106 USA
[7] Case Western Reserve Univ, Case Comprehens Canc Ctr, Sch Med, Cleveland, OH 44106 USA
[8] Cleveland Clin, Lerner Res Inst, Genome Ctr, Cleveland, OH 44195 USA
来源：
NATURE COMMUNICATIONS | 2025年 / 16卷 / 01期
关键词：
INVENTORY; DISCOVERY; DEMENTIA; TRIAL; SCALE;
D O I：
10.1038/s41467-025-56690-4
中图分类号：
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号：
07 ; 0710 ; 09 ;
摘要：
Repurposed drugs provide a rich source of potential therapies for Alzheimer's disease (AD) and other neurodegenerative disorders (NDD). Repurposed drugs have information from non-clinical studies, phase 1 dosing, and safety and tolerability data collected with the original indication. Computational approaches, "omic" studies, drug databases, and electronic medical records help identify candidate therapies. Generic repurposed agents lack intellectual property protection and are rarely advanced to late-stage trials for AD/NDD. In this review we define repurposing, describe the advantages and challenges of repurposing, offer strategies for overcoming the obstacles, and describe the key contributions of repurposing to the drug development ecosystem.
引用
收藏
页数：10
相关论文
共 50 条
  • [1] Melatonin in Alzheimer's disease and other neurodegenerative disorders
    Srinivasan V.
    Pandi-Perumal S.R.
    Cardinali D.P.
    Poeggeler B.
    Hardeland R.
    Behavioral and Brain Functions, 2 (1)
  • [2] Immune therapy of Alzheimer's disease and other neurodegenerative disorders
    Dodel, R.
    JOURNAL OF NEURAL TRANSMISSION, 2007, 114 (07) : CIX - CIX
  • [3] Akt activity in Alzheimer's disease and other neurodegenerative disorders
    Rickle, A
    Bogdanovic, N
    Volkman, I
    Winblad, B
    Ravid, R
    Cowburn, RF
    NEUROREPORT, 2004, 15 (06) : 955 - 959
  • [4] The molecular bases of Alzheimer's disease and other neurodegenerative disorders
    Maccioni, RB
    Muñoz, JP
    Barbeito, L
    ARCHIVES OF MEDICAL RESEARCH, 2001, 32 (05) : 367 - 381
  • [5] Metalloproteinases and their tissue inhibitors in Alzheimer's disease and other neurodegenerative disorders
    Rivera, Santiago
    Garcia-Gonzalez, Laura
    Khrestchatisky, Michel
    Baranger, Kevin
    CELLULAR AND MOLECULAR LIFE SCIENCES, 2019, 76 (16) : 3167 - 3191
  • [6] Microglia: Formidable Players in Alzheimer's Disease and Other Neurodegenerative Disorders
    Maiese, Kenneth
    CURRENT NEUROVASCULAR RESEARCH, 2023, 20 (05) : 515 - 518
  • [7] Pupil response to tropicamide in Alzheimer's disease and other neurodegenerative disorders
    GomezTortosa, E
    delBarrio, A
    JimenezAlfaro, I
    ACTA NEUROLOGICA SCANDINAVICA, 1996, 94 (02): : 104 - 109
  • [8] Tocopherol (Vitamin E) in Alzheimer’s Disease and Other Neurodegenerative Disorders
    Karen Berman
    Henry Brodaty
    CNS Drugs, 2004, 18 : 807 - 825
  • [9] Metalloproteinases and their tissue inhibitors in Alzheimer’s disease and other neurodegenerative disorders
    Santiago Rivera
    Laura García-González
    Michel Khrestchatisky
    Kévin Baranger
    Cellular and Molecular Life Sciences, 2019, 76 : 3167 - 3191
  • [10] Tocopherol (vitamin E) in Alzheimer's disease and other neurodegenerative disorders
    Berman, K
    Brodaty, H
    CNS DRUGS, 2004, 18 (12) : 807 - 825
12345